Home
overview

The Anti-Viral's market is forecast to grow to $14 billion by the year 2007 due to the escalation of viral infections and inadequate efficacy of current drugs available. Understanding the latest developments in anti-viral research, drug discovery and development activity is now more important than ever.

This conference will focus primarily on the major viral diseases such as Hepatitis, HIV, RSV and influenza, with a view to understanding the latest emerging viral diseases and the therapeutic treatments available.


A unique opportunity to learn from leading industry experts including:

  • Dr John Thomson, Vice President, Research, Vertex Pharmaceuticals
  • Dr Manos Perros, Director & Head, Anti-Infectives Biology, Pfizer
  • Dr Jang Han, Director, HCV Research, Chiron
  • Dr Kenny Simmen, Director, Research, HCV, Tibotec BVBA
  • Prof Patrick Iversen, Senior Vice President, Research & Development, AVI BioPharma
  • Dr Bert Klebl, Vice President, Research, Axxima Pharmaceuticals
  • Dr Mike Westby, HIV Virology Team Leader, Pfizer
  • Dr Steve Carroll, Senior Research Fellow, Merck

The essential event on:

  • NEW STRATEGIES AGAINST HCV, HIV, RSV & INFLUENZA: Learn about the latest research in these areas and where the approaches are leading
  • EMERGING VIRAL DISEASES: Identification methods and treatment strategies for West Nile Virus, Dengue, Ebola/ Marburg and Calicivirus
  • ANTI-VIRALS IN DEVELOPING COUNTRIES: How effective will ARV be in the developing countries?
  • ALTERNATIVE THERAPEUTIC APPROACHES: Hear about therapeutic vaccination and protein-based HIV therapeutics
  • KEY INDUSTRY PERSONNEL: Meet the leaders in the field, learn from their experiences and make valuable contacts

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Professor John Oxford

Professor John Oxford, Professor, Virology, The Royal London Hospital & Scientific Director, Retroscreen Virology

9:10 LATEST TRENDS, TECHNOLOGIES AND STRATEGIES IN ANTI-VIRALS

Dr Manos Perros

Dr Manos Perros, Director & Head, Anti-Infectives Biology, Pfizer

  • Chronic and acute viral infections
  • Different pathogens: HIV, HCV, HBV, respiratory viruses
  • Impact of diagnostics
  • Managing drug resistance
  • Application of new technologies and concepts in the treatment of viral infections
  • 9:50 NEXT GENERATION ANTI-VIRAL DRUG DISCOVERY AND DEVELOPMENT

    Dr Kenny Simmen

    Dr Kenny Simmen, Director, Research, HCV, Tibotec BVBA

  • Discovery and development of TMC 114, a next generation HIV PI
  • Structural and thermodynamics basis for TMC 114 unique properties
  • Clinical update on TMC 114 and TMC 125 studies in HIV-infected patients
  • Strategies in HCV drug discovery
  • 10:30 Morning Coffee

    11:00 MECHANISM BASED DESIGN OF SYNERGISTIC THERAPEUTICS FOR HEPATITIS C

    Dr John Thomson

    Dr John Thomson, Vice President, Research, Vertex Pharmaceuticals

  • HCV biology: targeting host and virus
  • Merimepodib and IMPDH inhibition
  • VX-950 and NS3·4A protease inhibitor design
  • Stochastic kinetics and fast versus slow mechanisms in inhibitor design
  • Viral rebound versus extinction
  • 11:40 HCV THERAPEUTICS BASED ON RNAi

    Dr Jang Han

    Dr Jang Han, Director, HCV Research, Chiron

    12:20 Networking Lunch

    13:50 PROGRESS TOWARDS SMALL MOLECULE DRUG DEVELOPMENT FOR HEPATITIS C VIRUS INFECTION

    Dr Steve Carroll

    Dr Steve Carroll, Senior Research Fellow, Merck

  • Viral enzyme targets
  • Protease inhibitors
  • Polymerase inhibitors –nucleoside analogues
  • Polymerase inhibitors –nonnucleosides
  • Impact of genotype variation
  • Prospects for combination therapies
  • 14:30 HOST CELL TARGETS IN HCV THERAPY

    Dr Bert Klebl

    Dr Bert Klebl, Vice President, Research, Axxima Pharmaceuticals

  • Current HCV treatments prove the host cell target strategy
  • Gastrointestinal Glutathionperoxidase (GI-GPx) as a host cell target for HCV
  • How to modulate GI-GPx with a small molecule
  • BioIogical activity of an GI-GPx activator in the replicon system
  • Efficacy of the GI-GPx activator in a clinical pilot trial
  • The GI-GPx activator as the third active principle in HCV therapy
  • 15:10 Afternoon Tea

    15:40 CHALLENGES IN HUMAN IMMUNODEFICIENCY VIRUS-RESEARCH

    Dr Mike Westby

    Dr Mike Westby, HIV Virology Team Leader, Pfizer

  • Current and emerging therapies
  • Current treatment options
  • Meeting the challenges of discovering new drugs for ‘old’ targets
  • The hurdles facing the emerging drugs for ‘new’ targets
  • Integrase and RNase H
  • CCR5 as the first host target in HIV
  • Gp120 inhibitors
  • The future
  • 16:20 PHOSPHOTRANSFERASE INHIBITORS: A MECHANISM BASED APPROACH TO NEW ANTI-VIRAL AGENTS

    Dr Jay Grobler

    Dr Jay Grobler, Research Fellow, Merck

  • Identifying integrase inhibitors with potent anti-viral activity in vitro and in vivo
  • Defining biochemical mechanisms
  • Using resistance to facilitate drug development
  • Exploiting ‘pharmacophore libraries’ to identify leads for novel targets
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Bert Klebl

    Dr Bert Klebl, Vice President, Research, Axxima Pharmaceuticals

    9:10 HUMAN MONOCLONAL ANTIBODIES HAVE A KEY ROLE TO PLAY IN THE FIGHT AGAINST HIV-1 INFECTION

    Dr Simon Lennard

    Dr Simon Lennard, Project Manager, Cambridge Antibody Technology

  • A programme focussed on the research and development of products specific for a key target involved in disease mediated by HIV-1
  • Providing important new information about the mechanism of HIV-1infection, potentially moving us one step closer to a successful vaccine for HIV-1
  • 9:50 NEW ANTI-VIRALS FROM ‘OLD’ TARGETS

    Dr Simon Tucker

    Dr Simon Tucker, Director, Research, Biota Holdings

  • Update on new NA inhibitors for influenza
  • New capsid binders for rhinovirus
  • New RSV anti-virals
  • New approaches to nucleotide-based anti-virals
  • 10:30 Morning Coffee

    11:00 A NOVEL INHIBITOR OF RESPIRATORY SYNCYTIAL VIRUS

    Stuart Cockerill

    Stuart Cockerill, Research Director, Arrow Therapeutics Ltd

  • Characterisation and mode of action
  • Preclinical analysis
  • 11:40 INFLUENZA

    Professor John Oxford

    Professor John Oxford, Professor, Virology, The Royal London Hospital & Scientific Director, Retroscreen Virology

  • The range of anti-flu drugs
  • New approach to finding novel inhibitor
  • Pandemic planning
  • A focus on the 1918 pandemic
  • 12:20 Networking Lunch

    13:50 INCREASING THE NEED FOR ANTI-VIRALS IN DEVELOPING COUNTRIES

    Dr Remko Van Leeuwen

    Dr Remko Van Leeuwen, Director, Business Development, International Antiviral Therapy Evaluation Centre

  • What is the need for ARVs?
  • How effective will ARVs be in developing countries?
  • Will ARVs affect the total number of people with HIV?
  • What are the issues that would need to be addressed in
  • determining the costs and the benefits of ARV therapy for people with HIV/ AIDS
  • 14:30 NOVEL APPROACHES TO THERAPEUTIC VACCINATION AGAINST CHRONIC VIRUS INFECTIONS

    Dr Joerg Schneider

    Dr Joerg Schneider, Vice President, Research, Oxxon tTerapeutics

  • Rationale for therapeutic vaccination
  • Preclinical data
  • Lessons from cancer vaccines
  • Clinical development
  • Challenges and perspectives
  • 15:10 Chairman's Closing Remarks followed by Afternoon Tea

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.